167 related articles for article (PubMed ID: 31385978)
1. Compliance with patient-reported outcome assessment in glioma patients: predictors for drop out.
Renovanz M; Hechtner M; Kohlmann K; Janko M; Nadji-Ohl M; Singer S; Ringel F; Coburger J; Hickmann AK
Neurooncol Pract; 2018 May; 5(2):129-138. PubMed ID: 31385978
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of health-related quality of life in Lithuanian brain tumor patients using the EORTC brain cancer module.
Bunevičius A; Tamašauskas Š; Tamašauskas A; Deltuva V
Medicina (Kaunas); 2012; 48(11):588-94. PubMed ID: 23455894
[TBL] [Abstract][Full Text] [Related]
3. Does preoperative health-related quality of life predict survival in high-grade glioma patients? - a prospective study.
Haraldseide LM; Jakola AS; Solheim O; Sagberg LM
Br J Neurosurg; 2020 Feb; 34(1):28-34. PubMed ID: 31809598
[No Abstract] [Full Text] [Related]
4. Translation and validation of the Urdu version of the European organization for research and treatment of cancer core quality of life questionnaire (EORTC QLQ-C30) and brain module (QLQ-BN20) in primary brain tumor patients.
Zahid N; Martins RS; Zahid W; Khalid W; Azam I; Bhamani SS; Asad N; Ahmad K; Jabbar AA; Shamim MS; Khan RJ; Javed G; Bari E; Enam SA
J Patient Rep Outcomes; 2021 Sep; 5(1):79. PubMed ID: 34487251
[TBL] [Abstract][Full Text] [Related]
5. Evaluating patients for psychosocial distress and supportive care needs based on health-related quality of life in primary brain tumors: a prospective multicenter analysis of patients with gliomas in an outpatient setting.
Hickmann AK; Hechtner M; Nadji-Ohl M; Janko M; Reuter AK; Kohlmann K; Haug M; Grüninger S; Deininger M; Ganslandt O; König J; Wirtz CR; Coburger J; Renovanz M
J Neurooncol; 2017 Jan; 131(1):135-151. PubMed ID: 27638638
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and patient-reported outcomes associated with dropout in severely affected oncological patients: an exploratory study.
Gebert P; Schindel D; Frick J; Schenk L; Grittner U
BMC Med Res Methodol; 2021 Apr; 21(1):77. PubMed ID: 33879087
[TBL] [Abstract][Full Text] [Related]
7. Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL.
Caissie A; Nguyen J; Chen E; Zhang L; Sahgal A; Clemons M; Kerba M; Arnalot PF; Danjoux C; Tsao M; Barnes E; Holden L; Danielson B; Chow E
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1238-45. PubMed ID: 22172909
[TBL] [Abstract][Full Text] [Related]
8. Assessing psychological and supportive care needs in glioma patients - feasibility study on the use of the Supportive Care Needs Survey Short Form (SCNS-SF34-G) and the Supportive Care Needs Survey Screening Tool (SCNS-ST9) in clinical practice.
Renovanz M; Hickmann AK; Coburger J; Kohlmann K; Janko M; Reuter AK; Keric N; Nadji-Ohl M; König J; Singer S; Giese A; Hechtner M
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 27774664
[TBL] [Abstract][Full Text] [Related]
9. Assessment Practice of Patient-Centered Outcomes in Surgical Neuro-Oncology: Survey-Based Recommendations for Clinical Routine.
Weiss Lucas C; Renovanz M; Jost J; Sabel M; Wiewrodt D; Rapp M
Front Oncol; 2021; 11():702017. PubMed ID: 34458144
[TBL] [Abstract][Full Text] [Related]
10. Quality of life in patients with primary and metastatic brain cancer as reported in the literature using the EORTC QLQ-BN20 and QLQ-C30.
Chiu L; Chiu N; Zeng L; Zhang L; Popovic M; Chow R; Lam H; Poon M; Chow E
Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):831-7. PubMed ID: 23252363
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
12. Supportive Care Needs in Glioma Patients and Their Caregivers in Clinical Practice: Results of a Multicenter Cross-Sectional Study.
Renovanz M; Maurer D; Lahr H; Weimann E; Deininger M; Wirtz CR; Ringel F; Singer S; Coburger J
Front Neurol; 2018; 9():763. PubMed ID: 30254605
[No Abstract] [Full Text] [Related]
13. Correlation of psychooncological distress- screening and quality of life assessment in neurosurgical patients.
Hoffmann K; Kamp M; Steiger HJ; Sabel M; Rapp M
Oncotarget; 2017 Dec; 8(67):111396-111404. PubMed ID: 29340062
[TBL] [Abstract][Full Text] [Related]
14. The EORTC QLQ-BN20 for assessment of quality of life in patients receiving treatment or prophylaxis for brain metastases: a literature review.
Leung A; Lien K; Zeng L; Nguyen J; Caissie A; Culleton S; Holden L; Chow E
Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):693-700. PubMed ID: 22098285
[TBL] [Abstract][Full Text] [Related]
15. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients.
Taphoorn MJ; Claassens L; Aaronson NK; Coens C; Mauer M; Osoba D; Stupp R; Mirimanoff RO; van den Bent MJ; Bottomley A;
Eur J Cancer; 2010 Apr; 46(6):1033-40. PubMed ID: 20181476
[TBL] [Abstract][Full Text] [Related]
16. Association of thyroid hormone concentrations with quality of life of primary brain tumor patients: a pilot study.
Bunevicius A; Laws ER; Deltuva V; Tamasauskas A
J Neurooncol; 2017 Jan; 131(2):385-391. PubMed ID: 27830477
[TBL] [Abstract][Full Text] [Related]
17. Prospective Longitudinal Assessment of Quality of Life and Activities of Daily Living as Patient-Reported Outcome Measures in Recurrent/Progressive Glioma Treated with High-dose Salvage Re-irradiation.
Maitre P; Gupta T; Maitre M; Goda J; Krishnatry R; Chatterjee A; Sridhar E; Sahay A; Mokal S; Moiyadi A; Shetty P; Patil V; Jalali R
Clin Oncol (R Coll Radiol); 2021 Mar; 33(3):e155-e165. PubMed ID: 32917486
[TBL] [Abstract][Full Text] [Related]
18. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
19. Validation and comparison of the health-related quality-of-life instruments EORTC QLQ-C30 and SF-36 in assessment of patients with chronic nonmalignant pain.
Fredheim OM; Borchgrevink PC; Saltnes T; Kaasa S
J Pain Symptom Manage; 2007 Dec; 34(6):657-65. PubMed ID: 17618079
[TBL] [Abstract][Full Text] [Related]
20. Normative data for the EORTC QLQ-C30 from the Austrian general population.
Lehmann J; Giesinger JM; Nolte S; Sztankay M; Wintner LM; Liegl G; Rose M; Holzner B;
Health Qual Life Outcomes; 2020 Aug; 18(1):275. PubMed ID: 32787854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
